PTPRC and neoplasm: Both mHAd.sT and mHAdLyp.sT treatment significantly increased M1 macrophage (CD11C+) percentages among F4/80+CD45+ cells in blood and tumor samples (Fig. 5A, blood, the fourth panel; Fig. 5C, tumor, the third panel, P < 0.01 or P < 0.05 vs buffer).